Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Affordability of risperidone and aripiprazole for the treatment of autism spectrum disorder
- At: Glasgow (Scotland) (2018)
- Type: Poster
- Poster code: POS-HMI-035
- By: SADAF, Shaista (University of Malta, Department of Pharmacy)
- Co-author(s): Shaista Sadaf: Department of Pharmacy, University of Malta, Msida, Malta
Maresca Attard Pizzuto: Department of Pharmacy, University of Malta, Msida, Malta
Luana Mifsud Buhagiar: Department of Pharmacy, University of Malta, Msida, Malta
Maurice Zarb Adami: Department of Pharmacy, University of Malta, Msida, Malta
Anthony Serracino Inglott: Department of Pharmacy, University of Malta, Msida, Malta - Abstract:
Background
The use of risperidone and aripiprazole in children and adolescents with Autism Spectrum Disorder (ASD) is off-label in India and Malta and is not included in the national formularies. The European Medicines Agency and the Central Drug Standard Control Organisation (India) have not approved the drug for the indication of ASD.Methods
A.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023